{"entity":{"id":"idea-fund-organoid-translation-gate","kind":"idea","name":"A funded organoid and PDX panel as the go/no-go gate before IND-enabling money","aka":[],"tldr":"Before any academic compound gets money for pre-trial studies, it would have to show activity in a standard panel of patient-derived tumour models run by an independent centre, so weak candidates are stopped early.","summary":"A central facility maintains a standardised, molecularly characterised panel of patient-derived organoids and xenografts across cancer types (drawing on EurOPDX, the NCI Patient-Derived Models Repository and Human Cancer Models Initiative collections) and tests every candidate nominated for IND-enabling funding in a blinded, pre-registered protocol with clinically relevant exposure. Results are published regardless of outcome. Funding for toxicology and CMC is contingent on passing pre-agreed activity criteria. This replaces the variable, investigator-run efficacy evidence that currently supports translational decisions.","asOf":"2026-09-08","links":[{"label":"NCI Patient-Derived Models Repository","url":"https://pdmr.cancer.gov/"}],"tags":[],"related":["cancer-models","idea-fund-replication-set-aside","idea-fund-ind-enabling-fund","idea-organoid-guided-adc"],"cancers":[],"sections":[],"technologies":["organoids","pdx-models","functional-drug-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-translational-valley","b-preclinical-models"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Candidates that pass an independent, blinded PDX/organoid gate have a phase 2 objective response or progression-free survival signal at least twice as often as historical academic candidates that were advanced on investigator-generated data alone.","rationale":"Retrospective studies show PDX and organoid response tracks patient response for many drug classes; NCI's PDMR and EurOPDX exist but are not used as a formal gate. Independent, blinded testing addresses the reproducibility and selection biases that inflate academic efficacy claims.","test":"Gate one translational fund's candidates for three years, publishing pass and fail results, and compare downstream clinical signals with the fund's prior ungated cohort.","maturity":"preclinical-evidence","actor":"research","cost":"medium","horizonYears":3},"route":"/ideas/idea-fund-organoid-translation-gate/","neighbours":{"collection":[{"id":"cancer-models","kind":"collection","name":"Cancer Models (PDCM Finder) & HCMI","route":"/collections/cancer-models/"}],"idea":[{"id":"idea-fund-ind-enabling-fund","kind":"idea","name":"A fast IND-enabling fund that pays for toxicology and manufacturing in eight weeks","route":"/ideas/idea-fund-ind-enabling-fund/"},{"id":"idea-organoid-guided-adc","kind":"idea","name":"Patient-derived organoids to pick ADC payloads","route":"/ideas/idea-organoid-guided-adc/"},{"id":"idea-fund-replication-set-aside","kind":"idea","name":"Set aside 3% of grant budgets to replicate findings before translation","route":"/ideas/idea-fund-replication-set-aside/"}],"technology":[{"id":"functional-drug-testing","kind":"technology","name":"Functional (ex vivo) drug testing","route":"/technologies/functional-drug-testing/"},{"id":"organoids","kind":"technology","name":"Patient-derived organoids","route":"/technologies/organoids/"},{"id":"pdx-models","kind":"technology","name":"Patient-derived xenografts","route":"/technologies/pdx-models/"}],"bottleneck":[{"id":"b-preclinical-models","kind":"bottleneck","name":"Lab models that fail to predict what happens in patients","route":"/bottlenecks/b-preclinical-models/"},{"id":"b-translational-valley","kind":"bottleneck","name":"The valley of death between lab and product","route":"/bottlenecks/b-translational-valley/"}]}}